Regulation of striatal neuropeptide mRNAs: effects of the 5-HT(2) antagonist SR46349B in adult rats with a neonatal 6-hydroxydopamine lesion.
The intrastriatal injection of 6-hydroxydopamine (6-OHDA) in newborn rats produces a marked striatal dopamine (DA) depletion, accompanied by a serotonin (5-HT) hyperinnervation and an up-regulation of 5-HT receptors. The aim of the present study was to investigate whether the increase in 5-HT(2) receptors could compensate for some of the DA lesion-induced effects, such as the increase in striatal preproenkephalin (PPE) and the decrease in preprotachykinin A (PPT-A) mRNA levels. Three months after the DA lesion, the effect of the selective 5-HT(2) antagonist SR46349B was investigated by a subacute treatment (10 mg/kg, IP, twice per day for 3.5 days). In sham-operated rats, the blockade of 5-HT(2) receptors decreased PPE mRNA levels in the striatum and, by contrast, had no effect on PPT-A mRNA levels. In rats with a unilateral neonatal DA lesion, SR46349B had no more effect on PPE mRNA levels in the intact striatum and was unable to modify the lesion induced-increase in PPE mRNA. The decrease in PPT-A mRNA levels induced by the neonatal DA lesion was not changed after SR46349B treatment in the posterior part of the lesioned striatum. Our results suggest that SR46349B indirectly decreases PPE mRNA levels in striatopallidal neurons in intact animals through a desinhibition of DA neuron activity. This is further evidenced by the lack of PPE mRNA changes in the DA lesioned striatum despite the up-regulation of 5-HT(2) receptor transmission induced in this model. Finally, the absence of any effect of 5-HT(2) antagonist on the expression of PPT-A mRNA in intact animals is discussed. The precise role of 5-HT(2) receptor on PPT-A mRNA biosynthesis after a neonatal lesion should be clarified by further experiments using 5-HT(2) agonists.
Durand
C
C
Laboratoire de Neurochimie-Anatomie, Institut des Neurosciences, CNRS UMR 7624, Université Pierre et Marie Curie, Paris, France.
Mathieu-Kia
A M
AM
Besson
M-J
MJ
Penit-Soria
J
J
D000818:Animals; D000831:Animals, Newborn; D003714:Denervation; D004298:Dopamine / Q000172:deficiency*; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D004745:Enkephalins / Q000235:genetics; D005464:Fluorobenzenes / Q000494:pharmacology; D017072:Neostriatum / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009479:Neuropeptides / Q000235:genetics*; D016627:Oxidopamine / Q000494:pharmacology; D010636:Phenols / Q000494:pharmacology; D011498:Protein Precursors / Q000235:genetics; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000494:pharmacology; D013565:Sympatholytics / Q000494:pharmacology; D015320:Tachykinins / Q000235:genetics; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology
D004745:Enkephalins; D005464:Fluorobenzenes; D009479:Neuropeptides; D010636:Phenols; D011498:Protein Precursors; D012333:RNA, Messenger; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D013565:Sympatholytics; D015320:Tachykinins; C044206:preprotachykinin; C076033:SR 46349B; D012701:Serotonin; D016627:Oxidopamine; C033660:preproenkephalin; D004298:Dopamine